Impact of cefazolin co-administration with vancomycin to reduce development of vancomycin-intermediate Staphylococcus aureus

Development of antimicrobial resistance during monotherapy of complicated methicillin-resistant Staphylococcus aureus bacteremia is problematic due to cross-resistance between vancomycin (VAN) and daptomycin, the only approved agents for this condition. Our objective was to demonstrate that development of resistance under conditions of suboptimal VAN (200  mg q 12 h) exposure in S. aureus can be attenuated by addition of cefazolin (CFZ).
Source: Diagnostic Microbiology and Infectious Disease - Category: Microbiology Authors: Source Type: research